229 related articles for article (PubMed ID: 36229663)
21. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp.
Hassel JC; Berking C; Forschner A; Gebhardt C; Heinzerling L; Meier F; Ochsenreither S; Siveke J; Hauschild A; Schadendorf D
Eur J Cancer; 2023 Sep; 191():112986. PubMed ID: 37595494
[TBL] [Abstract][Full Text] [Related]
22. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.
Shoushtari AN; Ong LT; Schoder H; Singh-Kandah S; Abbate KT; Postow MA; Callahan MK; Wolchok J; Chapman PB; Panageas KS; Schwartz GK; Carvajal RD
Melanoma Res; 2016 Jun; 26(3):272-7. PubMed ID: 26795274
[TBL] [Abstract][Full Text] [Related]
24. A pilot study of sunitinib malate in patients with metastatic uveal melanoma.
Mahipal A; Tijani L; Chan K; Laudadio M; Mastrangelo MJ; Sato T
Melanoma Res; 2012 Dec; 22(6):440-6. PubMed ID: 23114504
[TBL] [Abstract][Full Text] [Related]
25. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma.
Ny L; Jespersen H; Karlsson J; Alsén S; Filges S; All-Eriksson C; Andersson B; Carneiro A; Helgadottir H; Levin M; Ljuslinder I; Olofsson Bagge R; Sah VR; Stierner U; Ståhlberg A; Ullenhag G; Nilsson LM; Nilsson JA
Nat Commun; 2021 Aug; 12(1):5155. PubMed ID: 34453044
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
Schinzari G; Rossi E; Cassano A; Dadduzio V; Quirino M; Pagliara M; Blasi MA; Barone C
Melanoma Res; 2017 Dec; 27(6):591-595. PubMed ID: 29076951
[TBL] [Abstract][Full Text] [Related]
27. Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma.
Al Balushi K; Al Hadhrami A; Balushi HA; Al Lawati A; Das S
Curr Drug Targets; 2024; 25(3):149-157. PubMed ID: 38115619
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report.
Reiter S; Schroeder C; Broche J; Sinnberg T; Bonzheim I; Süsskind D; Flatz L; Forschner A
Front Oncol; 2023; 13():1167791. PubMed ID: 37207136
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.
Maio M; Danielli R; Chiarion-Sileni V; Pigozzo J; Parmiani G; Ridolfi R; De Rosa F; Del Vecchio M; Di Guardo L; Queirolo P; Picasso V; Marchetti P; De Galitiis F; Mandalà M; Guida M; Simeone E; Ascierto PA
Ann Oncol; 2013 Nov; 24(11):2911-5. PubMed ID: 24067719
[TBL] [Abstract][Full Text] [Related]
30. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study.
Kal Omar R; Hagström A; Stålhammar G
Trials; 2023 Mar; 24(1):230. PubMed ID: 36966349
[TBL] [Abstract][Full Text] [Related]
32. Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives.
Comito F; Marchese PV; Ricci AD; Tober N; Peterle C; Sperandi F; Melotti B
Future Oncol; 2021 Nov; 17(33):4583-4606. PubMed ID: 34431316
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A
J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511
[TBL] [Abstract][Full Text] [Related]
34. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
Jespersen H; Olofsson Bagge R; Ullenhag G; Carneiro A; Helgadottir H; Ljuslinder I; Levin M; All-Eriksson C; Andersson B; Stierner U; Nilsson LM; Nilsson JA; Ny L
BMC Cancer; 2019 May; 19(1):415. PubMed ID: 31046743
[TBL] [Abstract][Full Text] [Related]
35. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.
Howlett S; Carter TJ; Shaw HM; Nathan PD
Ther Adv Med Oncol; 2023; 15():17588359231160140. PubMed ID: 36970111
[TBL] [Abstract][Full Text] [Related]
36. Gp-100 as a Novel Therapeutic Target in Uveal Melanoma.
Martinez-Perez D; Viñal D; Solares I; Espinosa E; Feliu J
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885078
[TBL] [Abstract][Full Text] [Related]
37. Tebentafusp in first-line melanoma trials: An outperforming outlier.
Olivier T; Prasad V
Transl Oncol; 2022 Jun; 20():101408. PubMed ID: 35364557
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
Bhatia S; Moon J; Margolin KA; Weber JS; Lao CD; Othus M; Aparicio AM; Ribas A; Sondak VK
PLoS One; 2012; 7(11):e48787. PubMed ID: 23226204
[TBL] [Abstract][Full Text] [Related]
39. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.
Tarhini AA; Frankel P; Margolin KA; Christensen S; Ruel C; Shipe-Spotloe J; Gandara DR; Chen A; Kirkwood JM
Clin Cancer Res; 2011 Oct; 17(20):6574-81. PubMed ID: 21880788
[TBL] [Abstract][Full Text] [Related]
40. Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.
Piperno-Neumann S; Diallo A; Etienne-Grimaldi MC; Bidard FC; Rodrigues M; Plancher C; Mariani P; Cassoux N; Decaudin D; Asselain B; Servois V
Oncologist; 2016 Mar; 21(3):281-2. PubMed ID: 26911405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
